{"analyses":[{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.75","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"1.08"},{"ciLowerLimit":"0.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.92","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"1.20"},{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.37","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"0.82"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"27"}],"title":"With event"},{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"85"}],"title":"Without event"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"112"},{"groupId":"OG003","value":"112"}],"units":"Participants"}],"description":"From definitive surgery to first instance of ipsilateral invasive breast tumor recurrence, local/regional invasive breast cancer recurrence, distant recurrence, or death from any cause. Number of Participants who Died Due to Any Cause or had a recurrence.","groups":[{"description":"Patients receive paclitaxel (pac) IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV","id":"OG000","title":"Arm 1 (Pac --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive bevacizumab (bev) IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\nbevacizumab: Given IV","id":"OG001","title":"Arm 2 (Pac + Bev --> ddAC + Bev)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\ncarboplatin: Given IV","id":"OG002","title":"Arm 3 (Pac + Carboplatin --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1, bev as in arm 2, and carboplatin as in arm 3.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\nbevacizumab: Given IV\n\ncarboplatin: Given IV","id":"OG003","title":"Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 10 years","title":"Recurrence-free Survival","type":"SECONDARY","unitOfMeasure":"Participants"}